Poitou P, Fouret C, Duffau E
Droit & Pharmacie, PAREXEL, 12 rue de Lorraine, 92300 Levallois-Perret, France.
Ann Pharm Fr. 2002 Sep;60(5):326-32.
In 1989, a European directive extended the definition of proprietary medicinal products, and consequently the necessity to hold a marketing authorization (MA), for all industrially manufactured products, including medicinal gases. In France, the directive 89/341/CEE was transposed in the French law on December 8(th), 1992 and France was the first Member State to implement provisions for the obtention of MAs for gases for medical use. Since then, France has stayed at the forefront in this area. Following the inclusion of gases in the scope of pharmaceutical products, gases require on MA obtained following the same methods as for drugs and be manufactured and distributed in authorized sites. Moreover, the European directive has led the French authorities to classify gases according to their use. Gases for medical use are thus considered either as medicinal products or as medical devices.
1989年,一项欧洲指令扩大了专利药品的定义,因此包括医用气体在内的所有工业制造产品都必须持有上市许可(MA)。在法国,89/341/CEE号指令于1992年12月8日被纳入法国法律,法国是第一个实施获取医用气体上市许可规定的成员国。从那时起,法国在这一领域一直处于领先地位。随着气体被纳入药品范围,气体需要按照与药品相同的方法获得上市许可,并在授权场所生产和销售。此外,欧洲指令促使法国当局根据气体的用途对其进行分类。因此,医用气体要么被视为药品,要么被视为医疗器械。